Do you want to read an article? Please log in or register.
Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial
Heart Failure
Related content
Cardiac Arrest or DeathHeart, Artery and Coronary DiseasesHeart Failure
Empagliflozin, Health Status, and Quality of Life in Patients with Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial
Circulation
Butler J, Filippatos G, Siddiqi TJ, Brueckmann M, Böhm M, Chopra V, Ferreira JP, Januzzi JL, Kaul S, Piña IL, Ponikowski P, Shah SJ, Senni M, Vedin O, Verma S, Peil B, Pocock SJ, Zannad F, Packer M, Anker SD
doi: 10.1161/CIRCULATIONAHA.121.057812
Heart, Artery and Coronary DiseasesHeart Failure
Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF)
Eur J Heart Fail.
Rickenbacher P, Kaufmann BA, Maeder MT, Bernheim A, Goetschalckx K, Pfister O, Pfisterer M, Brunner-La Rocca HP; TIME-CHF Investigators
doi: 10.1002/ejhf.798.
Heart Failure
Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial
J Am Coll Cardiol
Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, Sattar N, Brueckmann M, Jamal W, Cotton D, Iwata T, Zannad F, EMPEROR-Reduced Trial Committees and Investigators.
doi: 10.1016/j.jacc.2021.01.033
RECOMMENDED
Heart, Artery and Coronary DiseasesHeart Failure
Effect of Empagliflozin on the Clinical Stability of Patients with Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial
★ 3
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
Circulation
Packer M, Anker SD, Butler J, Filippatos GS, Ferreira JP, Pocock S, Carson PE, Anand IS, Doehner W, Haass M, Komajda M, Miller AB, Pehrson S, Teerlink JR, Brueckmann M, Jamal W, Zeller C, Schnaidt S, Zannad F, EMPEROR-Reduced Trial Committees and Investigators.
doi: 10.1161/CIRCULATIONAHA.120.051783
COMMENTED
Heart Failure
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials
★ 2
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
★ 3
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
Lancet
Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, Brueckmann M, Ofstad AP, Pfarr E, Jamal W, Packer M
doi: 10.1016/S0140-6736(20)31824-9
Atrial FibrillationHeart FailureHypertension
Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry
Eur J Heart Fail.
Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP, Parissis J, Laroche C, Piepoli MF, Fonseca C, Mebazaa A, Lund L, Ambrosio GA, Coats AJ, Ferrari R, Ruschitzka F, Maggioni AP, Filippatos G
doi: 10.1002/ejhf.813.
Heart Failure
One-Year Safety and Clinical Outcomes of a Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP-HF I) Trial: A Randomized Clinical Trial
JAMA Cardiol.
Shah SJ, Feldman T, Ricciardi MJ, Kahwash R, Lilly S, Litwin S, Nielsen CD, van der Harst P, Hoendermis E, Penicka M, Bartunek J, Fail PS, Kaye DM, Walton A, Petrie MC, Walker N, Basuray A, Yakubov S, Hummel SL, Chetcuti S, Forde-McLean R, Herrmann HC, Burkhoff D, Massaro JM, Cleland JGF, Mauri L
doi: 10.1001/
Heart Failure
Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial
Eur Heart J
Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, Rocca HB, Janssens S, Tsutsui H, Zhang J, Brueckmann M, Jamal W, Cotton D, Iwata T, Schnee J, Zannad F
doi: 10.1093/eurheartj/ehaa968
Heart Failure
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial
Circulation
Anker SD, Butler J, Filippatos G, Khan MS, Marx N, Lam CSP, Schnaidt S, Ofstad AP, Brueckmann M, Jamal W, Bocchi E, Ponikowski P, Perrone SV, Januzzi JL, Verma S, Böhm M, Ferreira JP, Pocock SJ, Zannad F, Packer M, EMPEROR-Reduced Trial Committees and Investigators.
doi: 10.1161/CIRCULATIONAHA.120.051824